Publications by authors named "Shania Muncil"
Mycobacteroides abscessus (M. ab) infections are innately resistant to most currently available antibiotics and present a growing, poorly addressed medical need. The existing treatment regimens are lengthy and produce inadequate outcomes for many patients.
View Article and Find Full Text PDFThe need for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) next-generation vaccines has been highlighted by the rise of variants of concern (VoCs) and the long-term threat of emerging coronaviruses. Here, we design and characterize four categories of engineered nanoparticle immunogens that recapitulate the structural and antigenic properties of the prefusion SARS-CoV-2 spike (S), S1, and receptor-binding domain (RBD). These immunogens induce robust S binding, ACE2 inhibition, and authentic and pseudovirus neutralizing antibodies against SARS-CoV-2.
View Article and Find Full Text PDFArticle Synopsis
- The need for next-generation SARS-CoV-2 vaccines is driven by the emergence of new variants and long-term coronavirus risks, leading to the creation of four types of engineered nanoparticle immunogens that mimic key parts of the virus.
- These immunogens successfully stimulated strong antibody responses in mice, with one type, the Spike-ferritin nanoparticle (SpFN), producing significantly higher neutralizing antibody levels after just one shot compared to convalescent serum.
- Immunizations with SpFN and another type, RBD-Ferritin nanoparticle (RFN), provided protection in mice against lethal SARS-CoV-2 infections and generated potent neutralizing antibodies against